Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Response-adapted Treatment Guided by Negative Minimal Residual Disease and Negative Imaging (MRDI) in Fit Patients Diagnosed With Multiple Myeloma Who Are Candidates for Bone Marrow Transplantation

NCT05697913 is registered in ClinicalTrials.gov with Hospital Galdakao-Usansolo as lead sponsor.

NCT NCT05697913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05697913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Response-adapted Treatment Guided by Negative Minimal Residual Disease and Negative Imaging (MRDI) in Fit Patients Diagnosed With Multiple Myeloma Who Are Candidates for Bone Marrow Transplantation
Lead sponsor
Hospital Galdakao-Usansolo
Phase
Not applicable
Overall status
Unknown status
Start date
July 1, 2014
Completion date
June 30, 2024
Enrollment
66 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma